Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Antibody responses to non-egg-based standard-dose cell-culture influenza vaccine (containing 15 µg hemagglutinin [HA]/component) and recombinant vaccine (containing 45 µg HA/component) during consecutive seasons have not been studied in the United States.
Methods: In a randomized trial of immunogenicity of quadrivalent influenza vaccines among healthcare personnel (HCP) aged 18-64 years over 2 consecutive seasons, HCP who received recombinant-HA influenza vaccine (RIV) or cell culture-based inactivated influenza vaccine (ccIIV) during the first season (year 1) were re-randomized the second season of 2019-2020 (year 2 [Y2]) to receive ccIIV or RIV, resulting in 4 ccIIV/RIV combinations. In Y2, hemagglutination inhibition antibody titers against reference cell-grown vaccine viruses were compared in each ccIIV/RIV group with titers among HCP randomized both seasons to receive egg-based, standard-dose inactivated influenza vaccine (IIV) using geometric mean titer (GMT) ratios of Y2 post-vaccination titers.
Results: Y2 data from 414 HCP were analyzed per protocol. Compared with 60 IIV/IIV recipients, 74 RIV/RIV and 106 ccIIV/RIV recipients showed significantly elevated GMT ratios (Bonferroni corrected P < .007) against all components except A(H3N2). Post-vaccination GMT ratios for ccIIV/ccIIV and RIV/ccIIV were not significantly elevated compared with IIV/IIV except for RIV/ccIIV against A(H1N1)pdm09.
Conclusions: In adult HCP, receipt of RIV in 2 consecutive seasons or the second season was more immunogenic than consecutive egg-based IIV for 3 of the 4 components of quadrivalent vaccine. Immunogenicity of ccIIV/ccIIV was similar to that of IIV/IIV. Differences in HA antigen content may play a role in immunogenicity of influenza vaccination in consecutive seasons.
Clinical Trials Registration: NCT03722589.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907492 | PMC |
| http://dx.doi.org/10.1093/cid/ciac683 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Relative vaccine effectiveness of high-dose vs. standard-dose influenza vaccine against clinical outcomes according to history of atrial fibrillation: a pre-specified analysis of the DANFLU-1 randomized trial.
Eur Heart J Open
September 2025
Department of Cardiology, Copenhagen University Hospital-Herlev and Gentofte, Copenhagen, Gentofte Hospitalsvej 8, 2900 Hellerup, Denmark.
Aims: Atrial fibrillation (AF) may be associated with adverse influenza-related outcomes. We assessed the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) vs. standard-dose (SD-IIV) inactivated influenza vaccination against cardiovascular and all-cause hospitalizations and all-cause mortality according to history of AF.
View Article and Find Full Text PDFOverview: We analysed Australian Immunisation Register (AIR) data, predominantly for National Immunisation Program funded vaccines, as at 2 April 2023 for children, adolescents and adults, focusing on the calendar year 2022 and on trends from previous years. This report aims to provide comprehensive analysis and interpretation of vaccination coverage data to inform immunisation policy and programs.
Children: Fully vaccinated coverage in Australian children in 2022 was 0.
Structure-guided loop grafting improves expression and stability of influenza neuraminidase for vaccine development.
Elife
September 2025
Chinese Academy of Medical Science Oxford Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Influenza virus neuraminidase (NA) is a crucial target for protective antibodies, yet the development of recombinant NA protein as a vaccine has been held back by instability and variable expression. We have taken a pragmatic approach to improving expression and stability of NA by grafting antigenic surface loops from low-expressing NA proteins onto the scaffold of high-expressing counterparts. The resulting hybrid proteins retained the antigenic properties of the loop donor while benefiting from the high-yield expression, stability, and tetrameric structure of the loop recipient.
View Article and Find Full Text PDFImpact of influenza on chronic obstructive pulmonary disease: pathophysiology, exacerbations, and preventive approaches.
Ther Adv Respir Dis
September 2025
Department of Respiratory Medicine, Shangyu People's Hospital of Shaoxing, Zhejiang, China.
Chronic obstructive pulmonary disease (COPD) is a prevalent respiratory condition associated with increased morbidity and mortality, particularly during respiratory infections such as influenza. The interaction between COPD and influenza is multifaceted, involving compromised immune responses, chronic inflammation, and impaired lung function. Influenza infection can exacerbate COPD, leading to acute exacerbations, hospitalizations, and higher mortality.
View Article and Find Full Text PDFCOVID-19 Vaccine Effectiveness Against Hospitalizations and Severe Outcomes in Kosovo, 2022-2024: A Test-Negative Case-Control Study.
Influenza Other Respir Viruses
September 2025
World Health Organization Regional Office for Europe, Copenhagen, Denmark.
Background: Few studies have evaluated COVID-19 vaccine effectiveness (VE) in middle-income countries, particularly in eastern Europe. We aimed to estimate COVID-19 VE against SARS-CoV-2-confirmed hospitalizations and severe outcomes in Kosovo.
Methods: We conducted a test-negative case-control study using data from Kosovo's severe acute respiratory infection (SARI) sentinel surveillance system from January 2022 to June 2024.